WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2), or
- acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration (see WARNINGS).
OptiMARK™ Pharmacy Bulk Package
OptiMARK™ 0.5 mmol/mL
OptiMARK® (gadoversetamide injection) is a formulation of a nonionic gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide (gadoversetamide), for use in magnetic resonance imaging (MRI). OptiMARK® Injection is to be administered by intravenous injection only. OptiMARK® Injection is provided as a sterile, nonpyrogenic, clear, colorless to pale yellow, aqueous solution of gadoversetamide. No preservative is added. Each mL of OptiMARK® Injection contains 330.9 mg of gadoversetamide (0.5 millimole), 28.4 mg of calcium versetamide sodium (0.05 millimole), 0.7 mg calcium chloride dihydrate (0.005 millimole), and water for injection. Sodium hydroxide and/or hydrochloric acid may have been added for pH adjustment.
CNS (CENTRAL NERVOUS SYSTEM)
OptiMARK® Injection is indicated for use with magnetic resonance imaging (MRI) in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues.
OptiMARK® Injection is indicated for use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.
Media Articles Related to Optimark (Gadoversetamide)
Advances in Companion Diagnostics and Precision Medicine Congress,25-26 April 2017, London
Source: Conferences News From Medical News Today [2017.03.15]
With only a few weeks to go Oxford Global are proud to bring to you the final agenda for the Advances in Companion Diagnostics and co-located Precision Medicine Congress to be held on the 25-26...
Diagnostic Mammograms Find More Cancers, and More False-Positives
Source: MedicineNet Mammogram Specialty [2017.02.28]
Title: Diagnostic Mammograms Find More Cancers, and More False-Positives
Category: Health News
Created: 2/28/2017 12:00:00 AM
Last Editorial Review: 2/28/2017 12:00:00 AM
Advances in Companion Diagnostics Congress - Pre-Congress Live Webinars: Register For Free
Source: Conferences News From Medical News Today [2017.02.10]
Pre-Congress Live Webinars: Register For Free 'Challenges in Developing Companion Diagnostics for Cancer and Immunology'Tuesday 14th February - 3.00 pm GMTCan't make the date?
Flexible future of point-of-care disease diagnostic
Source: Bird Flu / Avian Flu News From Medical News Today [2015.07.29]
The world-wide deployment of biomedical devices for health monitoring, point-of-care diagnostics and environmental sensing is hampered by their high cost that is not readily affordable for e.g.
Optimizing the Diagnosis of Celiac Disease
Source: Medscape Allergy & Clinical Immunology Headlines [2017.04.25]
This review provides a summary of recent advances in the diagnosis of celiac disease, focusing on diagnostic challenges and the phenotypical characterization of celiac subtypes.
Current Opinion in Gastroenterology
Published Studies Related to Optimark (Gadoversetamide)
Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. [2008.02.05]
CONCLUSIONS: Gadoversetamide-enhanced MRI using doses of > or = 0.2 mmol/kg is effective in the detection and assessment of both acute and chronic MI. This study represents the first multicenter trial designed to evaluate an imaging approach for detecting MI.
Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients. [2009.05]
OBJECTIVE: The pharmacokinetics of gadoversetamide were examined in pediatric patients scheduled to undergo contrast-enhanced MRI of the central nervous system... CONCLUSIONS: The pharmacokinetic behavior of gadoversetamide was not significantly altered by differences in age or sex in pediatric patients from 2 to 18 years of age. Although significant differences in volumes of distribution, and clearance occurred between the age groups, these differences appeared to depend on body size rather than on age in pediatric patients between 2 and 18 years of age.
Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. [2009.01]
Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder of patients with kidney disease that is associated with gadolinium-based contrast exposure... All 3 patients were treated early in their disease course with intravenous sodium thiosulfate and responded with improved skin changes and joint mobility.
Safety of gadoversetamide in patients with acute and chronic myocardial infarction. [2008.12]
PURPOSE: To assess the safety data from two large, multicenter, phase 2 trials on the use of gadoversetamide (OptiMARK, Tyco Healthcare/Mallinckrodt, St. Louis, MO) as a contrast agent in delayed hyperenhancement magnetic resonance imaging (DE-MRI) in patients with acute and chronic myocardial infarction (MI)... CONCLUSION: Gadoversetamide is safe for use in patients with acute or chronic MI up to a dose of 0.3 mmol/kg. (c) 2008 Wiley-Liss, Inc.
The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. [2006.12]
CONCLUSION: The administration of gadoversetamide injection (0.1 mmol/kg) was safe, well tolerated and produced clinically appropriate contrast enhancement for MRI of the CNS in the pediatric population.
Clinical Trials Related to Optimark (Gadoversetamide)
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients [Completed]
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) [Completed]
The purpose of this study is to look at the safety (what are the side effects) and efficacy
(how well does it work) of Gadavist when used for taking images of the brain and spine. The
results of the MRI with Gadavist Injection will be compared to the results of MR images
taken without contrast and with the results of the MR images taken with OptiMARK.
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection [Suspended]
The objective of this study is to prospectively monitor the incidence of adverse drug
reactions, specifically NSF during routine use of gadoversetamide in a large number of
patients with moderate renal insufficiency (eGFR 30-59) and severe renal insufficiency or
end-stage renal disease requiring dialysis (eGFR <30).
Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies [Recruiting]
This is a pilot study in a patient population with suspected Coronary Artery Disease CAD) as
defined by the presence of an abnormal nuclear (PET/SPECT) perfusion scan. In this study
design, PET/SPECT will serve as the comparative standard for presence of myocardial
ischemia. We intend to determine the accuracy of a novel MR technique for localization of
perfusion deficits in comparison to PET/SPECT.
This is not a study to specifically evaluate the efficacy or safety of the drugs but rather
the diagnostic accuracy of the cardiac MRI procedure as a whole
Identification of Adverse Plaque Characteristics by Coronary MR Angiography [Recruiting]
This is a pilot study to determine whether coronary magnetic resonance angiography(CMRA)can
identify adverse plaque characteristics (buildup of fat, cholesterol, calcium, and other
substances found in the blood) seen on coronary computed tomography angiography(CCTA) and
evaluate whether there is a relationship between the adverse plaque characteristics and the
presence of coronary artery wall inflammation.
Reports of Suspected Optimark (Gadoversetamide) Side Effects
Nephrogenic Systemic Fibrosis (177),
Mobility Decreased (87),
Skin Induration (80),
Emotional Distress (79),
Skin Tightness (78),
Oedema Peripheral (74),
Joint Range of Motion Decreased (64),
General Physical Health Deterioration (62), more >>
Page last updated: 2017-04-25